Expert Corner
Peptides Remain a Growth Story
Bachem\\\'s strategic refocus
Since we were among the very first to supply peptide chemists around the world with the necessary tools to make peptides and soon had the biggest selection of such amino acid derivatives available from stock
Clinical Trials in China
What are the prospects for conducting clinical trials in China There are a number of driving factors that make China very attractive for conducting clinical trials People are already aware of most of these factorsrelatively inexpensive market in China its growth potential and reasonably easy access to patients Additionally there has been an incr...
Effective Interactions
Institute - Industry
How different are the industryacademia relations in India compared with the US and European countries In India industryacademia interrelations are not very strong Both industry and academia are not taking necessary initiatives to strengthen the relations as they do not consider this as a priority issue On the contrary in the US and European coun...
M&A and Partnerships in Pharma
Rising opportunities
Where do the current partnering opportunities lie for Pharma and biotech Because RD productivity is a problem for pharma the partnering opportunities are basically seen in licensing and acquisitions There are many opportunities because this year itself you have seen the speed of deal making in the US and in Europe between all kind of companies on...
Industry-Academia Interactions
How different are the industryacademia relations in India compared with the US and European countries In India industryacademia interrelations are not very strong Both industry and academia are not taking necessary initiatives to strengthen the relations as they do not con
Public Private Partnerships
Why do you think PPPs are necessary in the current scenario The global pharmaceutical industry is in the middle of a pipeline crisis The number of incidences of approved drugs being withdrawn from the market and the molecules from development is increasing Added to this the looming loss of revenue from a number of blockbuster drugs going off paten...
Biosimilars
What lies ahead?
How different are Biosimilars from traditional generics in terms of manufacturing and approval The differences between traditional generics and biosimilars are really quite fundamental Biologicals are orders of magnitude more complex both in structure and in terms of impurity profile compared to small molecules As a consequence of this increased...
Biopharmaceutical Manufacturing
The challenges
How is India placed in this market India has kept excellent pace when it comes to adoption of international regulatory standards especially with respect to facility and equipments Indian companies have the muscle to build quality plants and machinery and this is evident from the highest number of US FDAapproved plants in India outside of USA An...
M&A in Pharma Expert Views
Sujay J Shetty, Associate Director, Pharma Life Sciences , Advisory Corporate Finance, PriceWaterhousecoopers, India
From and Indian biotech pharma companys pointofview what is better a partnership or an acquisition It is difficult to answer because it is different for each company It depends on the strategies and the objectives of the acquirer If they feel they have specific skills that they can tap into which can be better addressed in partnership for exampl...
